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Despite its physiological importance, no part of human leptin receptor (ObR) has been structurally char-
acterized before. In this issue of Structure, Carpenter et al. report the crystal structure of the leptin-
binding domain of human ObR in complex with the Fab fragment of an ObR-blocking monoclonal
antibody (9F8 mAb).The discovery of leptin (ob gene), an
adipose tissue-derived cytokine-like hor-
mone, led the scientific community to
focus attention on its role as an anorexic
hormone involved in the negative re-
gulation of food intake (Friedman and
Halaas, 1998). Leptin is now known to
participate in a wide range of biological
functions that include—in addition to its
function as an adipostat—glucose meta-
bolism, CD4+ T lymphocyte proliferation,
cytokine secretion, phagocytosis, regula-
tion of the hypothalamic-pituitary-adrenal
axis, reproduction, angiogenesis and car-
diovascular pathology, bone formation,
and apoptosis (La Cava and Matarese,
2004) (Figure 1). It is now well docu-
mented that leptin acts like a cytokine
hormone with many pleiotropic effects,
as well as that many effects of leptin are
acquired through systemic and peripheral
activities.
Leptin is a helical-cytokine structurally
similarly to interleukin (IL)-6, IL-12, and
IL-15. Its receptor (ObR) belongs to the
class I cytokine receptors, which includes
gp-130, the common signal transducing
component for the IL-6-related family of
cytokines (Tartaglia, 1997). Leptin is ex-pressed mostly in the adipose tissue and
at lower levels in the muscle, stomach,
and placenta (Friedman and Halaas,
1998). More recently, it has also been
shown that leptin can be expressed by
activated inflammatory T helper 1 lym-
phocytes in experimental autoimmune
encephalomyelitis, an animal model of
multiple sclerosis (Sanna et al., 2003).
Accordingly, ObR can be found not only
in the hypothalamus and adipose tis-
sue, but also on immune cells such as
T lymphocytes and monocytes, endothe-
lial cells, and CD34+ bone marrow precur-
sors (Figure 1).
To date, despite the extensive genetic
and cellular analysis, structural studies
of ObR were missing. In this issue
of Structure, Carpenter et al. (2012)
elegantly characterize the crystal struc-
ture of the Fab fragment of an anti-hObR
monoclonal antibody (9F8 mAb) (Fazeli
et al., 2006), both in its uncomplexed state
and bound to the leptin-binding domain
(LBD) of human ObR. Strikingly, 9F8
mAb is the only anti-human ObR neutral-
izing mAb described to date. The authors
crystallized 9F8 mAb in its uncomplexed
state and solved its crystal structure ata 2.3 A˚ resolution. They further solved
the structure of 9F8 Fab complexed with
LBD at 1.95 A˚ resolution using Fab-medi-
ated crystallization. Their study describes
the structure of the LBD-9F8 Fab complex
and the changes induced in 9F8 Fab by
LBD binding. The authors also con-
structed and characterized a molecular
docking model of the leptin-LBD com-
plex, which revealed how 9F8 Fab
can antagonize leptin signaling. Overall,
these findings provide new insight into
the mechanism of leptin binding to LBD
and the mechanism of 9F8 antagonism
of leptin signaling.
To date, the crystallization of isolated
LBD or a leptin-LBD complex has proven
difficult. Although there are numerous
possible reasons for this, a major factor
was likely the presence of several flexible
loops within LBD, which limit the surface
area amenable to crystal contact for-
mation. Fab-mediated crystallization is a
powerful tool to improve crystallization
of challenging proteins by stabilizing
dynamic regions, thus increasing the
hydrophilic surface area available for
crystal lattice formation and masking
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Figure 1. Pleiotropic Effects of Leptin and of ObR Neutralization
The figure shows that leptin induces pleiotropic effects through activation of
its receptor at central and peripheral levels, such as control of food intake,
increase of basal metabolism, and control of reproductive, pancreatic,
and pro-inflammatory immune responses (La Cava and Matarese, 2004).
ObR blockade with 9F8 could be utilized to control metabolic and immune
dysregulation. These combined approaches could be utilized to dampen
leptin resistance, inflammation, and autoimmunity though direct neutralization
of the leptin axis.
Structure
PreviewsLBD was successfully crys-
tallized. In the future, the use
of non-neutralizing anti-
bodies that bind either leptin
or LBD may facilitate crystal-
lization of the leptin-LBD
complex.
This work provides new
information at multiple levels.
First, 9F8 mAb binds within
the isolated LBD, with
a similar affinity to leptin,
and their binding is mutually
exclusive. Second, 9F8 Fab
was crystallized in both its
uncomplexed and receptor
bound forms, and changes
in 9F8 induced by LBD
binding were characterized.
9F8 mAb appears to be
a good template for struc-
ture-based design of a potent
leptin antagonist with strong
therapeutic potential. Third,
because it is predicted that
the epitopes of leptin and
9F8 Fab overlap by only
10%, 9F8 Fab can represent
a useful tool to mediate co-crystallization of LBD with potential
peptide or small molecule drug can-
didates. This first report of a crystal struc-
ture of the ObR can thus facilitate the
design of therapeutics modulating leptin
signaling.
Though the discovery of leptin ener-
gized the study of energy balance, much
of the initial enthusiasm waned with the
realization that obesity is not a condition
of leptin insufficiency but rather of leptin
resistance (Coll et al., 2007). Leptin re-
sistance is often described as a state in
which circulating levels are elevated with
concomitant hyperphagia and obesity.
By this standard, most obese individuals
are leptin resistant. From a molecular
standpoint, leptin resistance is a failure
of leptin to activate key signaling mole-
cules in target neurons. Although, leptin
activates multiple intracellular signaling
molecules whose resistance is often only
demonstrated for a few. There is also
evidence for variations in leptin-activated
STAT-3 in the brain so that leptin sensi-
tivity may vary even within the same indi-
vidual. What is known about leptin resis-
tance is that it involves at least two
separate mechanisms: the first being a
reduced transport across the blood brain386 Structure 20, March 7, 2012 ª2012 Elsevbarrier, and the second being a reduced
capacity for intracellular signaling within
target neurons (Coll et al., 2007) (Figure 1).
A reduction in leptin transport across
the blood brain barrier has been demon-
strated in obese animals. Additional
work has documented a reduced sensi-
tivity to peripheral leptin signaling prior
to loss of central leptin sensitivity, yet it
has not been demonstrated that alter-
ations in leptin transport directly influence
body weight or food intake in lean or
obese animals. As such, the role of
reduced transport in the etiology of
obesity is not fully clear (Coll et al.,
2007). Basing on these considerations,
a possibility should exist to reverse leptin
resistance in obesity by using anti-ObR
neutralizing antibodies, such as 9F8
mAb, followed by administration of re-
combinant leptin. This novel strategy
would be based on the possibility that
ObR neutralization with antibodies could
desensitize the ObR, and the subsequent
administration of recombinant leptin
would inhibit food intake—more effi-
ciently than using only leptin administra-
tion. ObR neutralization could also repre-
sent an alternative molecular tool in the
treatment of autoimmunity and inflamma-ier Ltd All rights reservedtion (De Rosa et al., 2006)
(Figure 1). Indeed, ObR
blockade reduces the activa-
tion of effector T cells and to
induce expansion in vitro of
regulatory T (Tregs), an
immune cell subset re-
sponsible for maintenance of
immune tolerance (De Rosa
et al., 2007). This effect could
be exploited to expand ex-
vivo Tregs from autoimmune
patients in which a specific
defect in Treg number has
been observed. Another
approach could be the use of
ObR neutralization in vivo for
the treatment of inflammation,
although this would generate
concerns related to the fact
that since ObR short forms
are expressed in many
tissues, neutralizing monoclo-
nals against the extracellular
domain could bind in many
tissues and determine poten-
tial tissue damage via
complement activation. The
generation of Fab fragments,such as in the case of 9F8, could possibly
reduce these adverse effects.
To conclude, there are still many ques-
tions about the role of many molecules at
the interface between metabolism and
immunity in the regulation of the two
systems. While new information is un-
veiling the complex connection between
metabolism and immunity, further re-
search is needed. Yet, the adipose tissue
can no longer be regarded merely as
a store of body fat, but rather as an active
participant in the regulation of essential
body processes with prominent roles,
particularly in the balance of inflammation
and immune homeostasis. In this con-
text, antagonism of the leptin axis could
represent a novel strategy to control
inflammation and peripheral leptin resis-
tance in obesity and related conditions,
to possibly develop novel therapeutic
strategies to treat obesity, metabolic
disorders, and immune dysregulation.ACKNOWLEDGMENTS
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After elucidation of the atomic details of 20S proteasomes, current research focuses on the regulatory 19S
particle. In this issue of Structure, He et al. present the crystal structure of Rpn2 and use electronmicroscopy
to examine differences between Rpn2 and Rpn1.Peptide bond hydrolysis constitutes an
essential intracellular process, enabling
amino acid recycling as well as control
of signaling cascades. Cytosolic protein
degradation is predominantly mediated
by the proteasome, a multicatalytic
protease, consisting of 28 subunits that
are stacked in four seven-membered
rings. Whereas the a subunits form the
outer rings of the barrel-shaped 20S
core particle (CP), the inner rings are
exclusively built of b subunits which
exert proteolytic activity. Archaeal CPs
bear only one type of a and b subunits
and thus harbor seven identical active
b subunits. In contrast, eukaryotes incor-
porate seven distinct a and b subunits in
their CPs, but only three out of the seven
b subunits are capable of proteolysis.
Apart from the constitutive proteasome,
mammals express two specialized
versions of CPs, namely the immuno-
and the thymoproteasome, which differ
in their set of catalytically active b subunits
and thus in their biological function.
During the last 15 years, the atomic
structure of CPs from different species
has been analyzed by X-ray crystallog-
raphy and, only recently, this collection
has been completed by the crystal struc-ture of the mouse immunoproteasome
(Huber et al., 2012). Additionally, ATP-
independent regulators of this destructive
machinery, namely 11S complexes and
Blm10, have been structurally investi-
gated. Sitting on top of the CP, the 11S
particle, a heptamer of helical monomers
arranged around a central pore, induces
conformational changes in the N-termini
of the a subunits, which ultimately results
in the opening of the entry gate to the
proteolytic chamber and provides access
for substrates (Whitby et al., 2000). In
contrast to 11S particles, the atomic
structure of Blm10 is indicative of in-
hibitory rather than stimulatory effects
on proteasomal activity (Sadre-Bazzaz
et al., 2010).
Despite a number of electron micros-
copy studies on the most prominent
regulatory particle (e.g., da Fonseca
and Morris, 2008), the 19S complex,
composed of at least 18 different poly-
peptides, has not yet been characterized
at atomic resolution. As an ATP-depen-
dent complex, the 19S cap of CPs
plays a key role in the recognition of ubi-
quitylated substrates and in their unfold-
ing and translocation into the proteolytic
chamber. Recent advance in this fieldis provided by an impressive study in
which the 19S particle has been recon-
stituted in Escherichia coli in order to
map the individual non-ATPase subunits,
termed ‘‘Rpn,’’ and the ATPase subunits
(‘‘Rpt’’) by electron microscopy (Lander
et al., 2012). Owing to the complex
architecture of the 19S cap, a crystallo-
graphic approach is quite challenging
and, hence, current research focuses
on the elucidation of the X-ray structures
of single subunits. In this regard, this
issue of Structure reports the crystal
structure of one of the largest 19S
subunits, namely Rpn2, solved by He
et al. (2012).
Rpn2 adopts a cylindrical shape con-
sisting of two layers of a helices that
are wrapped around each other. At the
N- and C terminus Rpn2 forms an elon-
gated a-helical segment and a globular
domain, respectively, which come close
to each other in the tertiary structure.
The toroid-like fold of Rpn2 results from
a repetitive primary sequence of 35–40
amino acids called proteasome/cyclo-
some (PC) motif (Kajava, 2002). Remark-
ably, the 32 HEAT repeats of Blm10
adopt a similar superhelical dome-like
structure, indicating that PC and HEATª2012 Elsevier Ltd All rights reserved 387
